--- title: "Ostarine (Enobosarm, MK-2866): Dosing & Vendor Prices" description: "Ostarine (Enobosarm, MK-2866): dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Ostarine (Enobosarm, MK-2866)" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Ostarine (Enobosarm, MK-2866)", "description": "Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. It was designed to switch on the androgen receptor in muscle and bone while acting only weakly on prostate and other reproductive tissue, and it was taken into clinical development for muscle wasting in cancer, for age-related loss of muscle, for androgen receptor positive breast cancer and for stress urinary incontinence. It has never been approved by the FDA or the EMA for any indication. Development rights now sit with Veru Inc, which is testing it as an add-on to GLP-1 receptor agonists to limit the loss of lean mass that accompanies rapid weight reduction. The androgen receptor is a nuclear receptor. Testosterone and dihydrotestosterone bind it, move it into the cell nucleus and change which genes are read. Enobosarm binds the same receptor but recruits a different set of co-regulator proteins, which is why its effects on muscle and bone are stronger than its effects on prostate and skin. Work in mice showed that the muscle response does not come only from satellite cells, since enobosarm still restored muscle weight in animals lacking the androgen receptor in that cell lineage (PMID: 26393303). In animals, enobosarm improved bone healing in ovariectomized rats (PMID: 31531719), improved muscle tissue in ovariectomized rats (PMID: 33042018) and improved bone in orchiectomized rats used as an osteoporosis model (PMID: 37378829). Not every animal result is favorable: in rats it blunted the effect of endurance training on submaximal endurance (PMID: 38451281) and did not add to the metabolic effect of exercise in obese rats (PMID: 37865959). In humans, a 12-week phase 2 trial in 120 healthy older men and postmenopausal women reported gains in total lean body mass and physical function against placebo (PMID: 22031847), and a phase 2 trial in patients with cancer-related weight loss reported gains in lean body mass (PMID: 23499390). The safety record is the part most often left out of marketing. Cholestatic and hepatocellular liver injury after ostarine use has been published as individual case reports, including a young man who needed albumin dialysis and took six months to return to normal bilirubin (PMID: 37871633), a hepatocellular case that resolved after stopping the supplement (PMID: 35655632) and cases involving ostarine with post-cycle drugs (PMID: 34141767). A systematic review of safety in healthy adults collected fifteen published cases of drug-induced liver injury across the SARM class along with a tendon rupture and a rhabdomyolysis case (PMID: 37218811). The FDA states that these products are unapproved drugs, are not dietary supplements, and lists liver injury and acute liver failure, heart attack, stroke, psychosis, infertility and testicular shrinkage among reported risks (FDA, Certain Bodybuilding Products Put Consumers at Risk, page updated December 2025). What is sold online is often not what the label says. In an analysis of 44 products marketed as SARMs, only 52 percent contained a SARM at all, 39 percent contained a different unapproved drug, and the labeled amount matched the measured amount in only 41 percent (PMID: 29183075).", "url": "https://www.bodyhackguide.co/compound/ostarine", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "74.99", "highPrice": "74.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "74.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/ostarine-mk-2866/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Ostarine (Enobosarm, MK-2866)", "description": "Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. It was designed to switch on the androgen receptor in muscle and bone while acting only weakly on prostate and other reproductive tissue, and it was taken into clinical development for muscle wasting in cancer, for age-related loss of muscle, for androgen receptor positive breast cancer and for stress urinary incontinence. It has never been approved by the FDA or the EMA for any indication. Development rights now sit with Veru Inc, which is testing it as an add-on to GLP-1 receptor agonists to limit the loss of lean mass that accompanies rapid weight reduction. The androgen receptor is a nuclear receptor. Testosterone and dihydrotestosterone bind it, move it into the cell nucleus and change which genes are read. Enobosarm binds the same receptor but recruits a different set of co-regulator proteins, which is why its effects on muscle and bone are stronger than its effects on prostate and skin. Work in mice showed that the muscle response does not come only from satellite cells, since enobosarm still restored muscle weight in animals lacking the androgen receptor in that cell lineage (PMID: 26393303). In animals, enobosarm improved bone healing in ovariectomized rats (PMID: 31531719), improved muscle tissue in ovariectomized rats (PMID: 33042018) and improved bone in orchiectomized rats used as an osteoporosis model (PMID: 37378829). Not every animal result is favorable: in rats it blunted the effect of endurance training on submaximal endurance (PMID: 38451281) and did not add to the metabolic effect of exercise in obese rats (PMID: 37865959). In humans, a 12-week phase 2 trial in 120 healthy older men and postmenopausal women reported gains in total lean body mass and physical function against placebo (PMID: 22031847), and a phase 2 trial in patients with cancer-related weight loss reported gains in lean body mass (PMID: 23499390). The safety record is the part most often left out of marketing. Cholestatic and hepatocellular liver injury after ostarine use has been published as individual case reports, including a young man who needed albumin dialysis and took six months to return to normal bilirubin (PMID: 37871633), a hepatocellular case that resolved after stopping the supplement (PMID: 35655632) and cases involving ostarine with post-cycle drugs (PMID: 34141767). A systematic review of safety in healthy adults collected fifteen published cases of drug-induced liver injury across the SARM class along with a tendon rupture and a rhabdomyolysis case (PMID: 37218811). The FDA states that these products are unapproved drugs, are not dietary supplements, and lists liver injury and acute liver failure, heart attack, stroke, psychosis, infertility and testicular shrinkage among reported risks (FDA, Certain Bodybuilding Products Put Consumers at Risk, page updated December 2025). What is sold online is often not what the label says. In an analysis of 44 products marketed as SARMs, only 52 percent contained a SARM at all, 39 percent contained a different unapproved drug, and the labeled amount matched the measured amount in only 41 percent (PMID: 29183075).", "lastReviewed": "2026-09-07T04:48:28.168Z", "url": "https://www.bodyhackguide.co/compound/ostarine", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Ostarine (Enobosarm, MK-2866)", "alternateName": [ "Enobosarm", "MK-2866", "MK2866", "GTx-024", "S-22", "Ostabolic" ], "description": "Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. It was designed to switch on the androgen receptor in muscle and bone while acting only weakly on prostate and other reproductive tissue, and it was taken into clinical development for muscle wasting in cancer, for age-related loss of muscle, for androgen receptor positive breast cancer and for stress urinary incontinence. It has never been approved by the FDA or the EMA for any indication. Development rights now sit with Veru Inc, which is testing it as an add-on to GLP-1 receptor agonists to limit the loss of lean mass that accompanies rapid weight reduction. The androgen receptor is a nuclear receptor. Testosterone and dihydrotestosterone bind it, move it into the cell nucleus and change which genes are read. Enobosarm binds the same receptor but recruits a different set of co-regulator proteins, which is why its effects on muscle and bone are stronger than its effects on prostate and skin. Work in mice showed that the muscle response does not come only from satellite cells, since enobosarm still restored muscle weight in animals lacking the androgen receptor in that cell lineage (PMID: 26393303). In animals, enobosarm improved bone healing in ovariectomized rats (PMID: 31531719), improved muscle tissue in ovariectomized rats (PMID: 33042018) and improved bone in orchiectomized rats used as an osteoporosis model (PMID: 37378829). Not every animal result is favorable: in rats it blunted the effect of endurance training on submaximal endurance (PMID: 38451281) and did not add to the metabolic effect of exercise in obese rats (PMID: 37865959). In humans, a 12-week phase 2 trial in 120 healthy older men and postmenopausal women reported gains in total lean body mass and physical function against placebo (PMID: 22031847), and a phase 2 trial in patients with cancer-related weight loss reported gains in lean body mass (PMID: 23499390). The safety record is the part most often left out of marketing. Cholestatic and hepatocellular liver injury after ostarine use has been published as individual case reports, including a young man who needed albumin dialysis and took six months to return to normal bilirubin (PMID: 37871633), a hepatocellular case that resolved after stopping the supplement (PMID: 35655632) and cases involving ostarine with post-cycle drugs (PMID: 34141767). A systematic review of safety in healthy adults collected fifteen published cases of drug-induced liver injury across the SARM class along with a tendon rupture and a rhabdomyolysis case (PMID: 37218811). The FDA states that these products are unapproved drugs, are not dietary supplements, and lists liver injury and acute liver failure, heart attack, stroke, psychosis, infertility and testicular shrinkage among reported risks (FDA, Certain Bodybuilding Products Put Consumers at Risk, page updated December 2025). What is sold online is often not what the label says. In an analysis of 44 products marketed as SARMs, only 52 percent contained a SARM at all, 39 percent contained a different unapproved drug, and the labeled amount matched the measured amount in only 41 percent (PMID: 29183075).", "activeIngredient": "Ostarine (Enobosarm, MK-2866)", "administrationRoute": "Oral", "mechanismOfAction": "Enobosarm is a nonsteroidal partial agonist of the androgen receptor. It binds the ligand-binding domain and drives nuclear translocation and transcription of androgen-responsive genes in skeletal muscle and bone, while producing weaker activation in prostate and other androgenic tissue, which is the basis for calling it tissue-selective. Mouse work indicates the anabolic signal is not confined to the satellite cell lineage, since enobosarm restored levator ani muscle weight in animals whose satellite cells lacked the androgen receptor, pointing to androgen receptor positive cells outside that lineage (PMID: 26393303). In humans the published record for enobosarm is limited to body composition and physical function endpoints: a 12-week phase 2 trial in 120 healthy older men and postmenopausal women reported dose-dependent gains in total lean body mass by DXA (PMID: 22031847).", "dosageForm": "capsule", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Ostarine (Enobosarm, MK-2866) used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. It was designed to switch on the androgen receptor in muscle and bone while acting only weakly on prostate and other reproductive tissue, and it was taken into clinical development for muscle wasting in cancer, for age-related loss of muscle, for androgen receptor positive breast cancer and for stress urinary incontinence. It has never been approved by the FDA or the EMA for any indication. Development rights now sit with Veru Inc, which is testing it as an add-on to GLP-1 receptor agonists to limit the loss of lean mass that accompanies rapid weight reduction. The androgen receptor is a nuclear receptor. Testosterone and dihydrotestosterone bind it, move it into the cell nucleus and change which genes are read. Enobosarm binds the same receptor but recruits a different set of co-regulator proteins, which is why its effects on muscle and bone are stronger than its effects on prostate and skin. Work in mice showed that the muscle response does not come only from satellite cells, since enobosarm still restored muscle weight in animals lacking the androgen receptor in that cell lineage (PMID: 26393303). In animals, enobosarm improved bone healing in ovariectomized rats (PMID: 31531719), improved muscle tissue in ovariectomized rats (PMID: 33042018) and improved bone in orchiectomized rats used as an osteoporosis model (PMID: 37378829). Not every animal result is favorable: in rats it blunted the effect of endurance training on submaximal endurance (PMID: 38451281) and did not add to the metabolic effect of exercise in obese rats (PMID: 37865959). In humans, a 12-week phase 2 trial in 120 healthy older men and postmenopausal women reported gains in total lean body mass and physical function against placebo (PMID: 22031847), and a phase 2 trial in patients with cancer-related weight loss reported gains in lean body mass (PMID: 23499390). The safety record is the part most often left out of marketing. Cholestatic and hepatocellular liver injury after ostarine use has been published as individual case reports, including a young man who needed albumin dialysis and took six months to return to normal bilirubin (PMID: 37871633), a hepatocellular case that resolved after stopping the supplement (PMID: 35655632) and cases involving ostarine with post-cycle drugs (PMID: 34141767). A systematic review of safety in healthy adults collected fifteen published cases of drug-induced liver injury across the SARM class along with a tendon rupture and a rhabdomyolysis case (PMID: 37218811). The FDA states that these products are unapproved drugs, are not dietary supplements, and lists liver injury and acute liver failure, heart attack, stroke, psychosis, infertility and testicular shrinkage among reported risks (FDA, Certain Bodybuilding Products Put Consumers at Risk, page updated December 2025). What is sold online is often not what the label says. In an analysis of 44 products marketed as SARMs, only 52 percent contained a SARM at all, 39 percent contained a different unapproved drug, and the labeled amount matched the measured amount in only 41 percent (PMID: 29183075)." } }, { "@type": "Question", "name": "What forms does Ostarine (Enobosarm, MK-2866) come in?", "acceptedAnswer": { "@type": "Answer", "text": "Ostarine (Enobosarm, MK-2866) is available in capsule form." } }, { "@type": "Question", "name": "How much does Ostarine (Enobosarm, MK-2866) cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $74.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Ostarine (Enobosarm, MK-2866) vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fostarine) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Ostarine (Enobosarm, MK-2866) [Where to buy Ostarine (Enobosarm, MK-2866)](/buy/ostarine) [Ostarine (Enobosarm, MK-2866) coupon codes](/coupons/ostarine) [Ostarine (Enobosarm, MK-2866) protocol](/protocol/ostarine) [Alternatives to Ostarine (Enobosarm, MK-2866)](/alternatives-to/ostarine) [Ostarine (Enobosarm, MK-2866) side effects](/side-effects/ostarine) 1. [Home](/) 3. [Compounds](/compare) 5. Ostarine (Enobosarm, MK-2866) ![Ostarine (Enobosarm, MK-2866) molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Ostarine (Enobosarm, MK-2866) Performance Phase 3 Download PDF Also known as: Enobosarm, MK-2866, MK2866, GTx-024, S-22, Ostabolic Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. It was designed to switch on the androgen receptor in muscle and bone while acting only weakly on prostate and other reproductive tissue, and it was taken into clinical development for muscle wasting in cancer, for age-related loss of muscle, for androgen receptor positive breast cancer and for stress urinary incontinence. Half-Life: Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861) Route: Oral MW: 389.33 g/mol CAS: 841205-47-8 Last reviewed: Sep 7, 2026 [ Performance Category ](/wiki#cat-performance) Phase 3 Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $74.99 60 capsules · capsule [Buy Now](https://disguisedalpha.com/product/ostarine-mk-2866/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Enobosarm is a nonsteroidal partial agonist of the androgen receptor. It binds the ligand-binding domain and drives nuclear translocation and transcription of androgen-responsive genes in skeletal muscle and bone, while producing weaker activation in prostate and other androgenic… Half-Life Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861) Routes Oral Potential Benefits Increased total lean body mass and improved physical function in healthy older men and postmenopausal women in a 12-week phase 2 trial (PMID: 22031847) Increased total lean body mass in patients with cancer-associated weight loss in a phase 2 trial (PMID: 23499390) Clinical benefit at 24 weeks in about a third of women with androgen receptor positive, estrogen receptor positive, HER2 negative advanced breast cancer in a phase 2 trial (PMID: 38342115) Improved bone healing in ovariectomized rats (PMID: 31531719) Improved muscle tissue in ovariectomized rats (PMID: 33042018) ### Overview Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. It was designed to switch on the androgen receptor in muscle and bone while acting only weakly on prostate and other reproductive tissue, and it was taken into clinical development for muscle wasting in cancer, for age-related loss of muscle, for androgen receptor positive breast cancer and for stress urinary incontinence. It has never been approved by the FDA or the EMA for any indication. Development rights now sit with Veru Inc, which is testing it as an add-on to GLP-1 receptor agonists to limit the loss of lean mass that accompanies rapid weight reduction. The androgen receptor is a nuclear receptor. Testosterone and dihydrotestosterone bind it, move it into the cell nucleus and change which genes are read. Enobosarm binds the same receptor but recruits a different set of co-regulator proteins, which is why its effects on muscle and bone are stronger than its effects on prostate and skin. Work in mice showed that the muscle response does not come only from satellite cells, since enobosarm still restored muscle weight in animals lacking the androgen receptor in that cell lineage (PMID: 26393303). In animals, enobosarm improved bone healing in ovariectomized rats (PMID: 31531719), improved muscle tissue in ovariectomized rats (PMID: 33042018) and improved bone in orchiectomized rats used as an osteoporosis model (PMID: 37378829). Not every animal result is favorable: in rats it blunted the effect of endurance training on submaximal endurance (PMID: 38451281) and did not add to the metabolic effect of exercise in obese rats (PMID: 37865959). In humans, a 12-week phase 2 trial in 120 healthy older men and postmenopausal women reported gains in total lean body mass and physical function against placebo (PMID: 22031847), and a phase 2 trial in patients with cancer-related weight loss reported gains in lean body mass (PMID: 23499390). The safety record is the part most often left out of marketing. Cholestatic and hepatocellular liver injury after ostarine use has been published as individual case reports, including a young man who needed albumin dialysis and took six months to return to normal bilirubin (PMID: 37871633), a hepatocellular case that resolved after stopping the supplement (PMID: 35655632) and cases involving ostarine with post-cycle drugs (PMID: 34141767). A systematic review of safety in healthy adults collected fifteen published cases of drug-induced liver injury across the SARM class along with a tendon rupture and a rhabdomyolysis case (PMID: 37218811). The FDA states that these products are unapproved drugs, are not dietary supplements, and lists liver injury and acute liver failure, heart attack, stroke, psychosis, infertility and testicular shrinkage among reported risks (FDA, Certain Bodybuilding Products Put Consumers at Risk, page updated December 2025). What is sold online is often not what the label says. In an analysis of 44 products marketed as SARMs, only 52 percent contained a SARM at all, 39 percent contained a different unapproved drug, and the labeled amount matched the measured amount in only 41 percent (PMID: 29183075). ### Potential Research Fields Muscle wasting and cachexia Sarcopenia Oncology Sports drug testing ## Chemical Information IUPAC Name Not yet available CAS Number 841205-47-8 Molecular Formula C19H14F3N3O3 Molecular Mass 389.33 g/mol ![Ostarine (Enobosarm, MK-2866) molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/11326715/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/11326715) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications Mechanism-based: androgen receptor agonists are contraindicated in pregnancy because of the risk of virilizing a female fetus, and in men with known or suspected prostate cancer, since androgen receptor activation can drive prostate tissue. Existing liver disease or raised transaminases is a mechanism-based and case-report-based reason to avoid it, given published cholestatic and hepatocellular injury (PMID: 37871633, PMID: 35655632). Athletes in tested sport must avoid it because it is prohibited at all times (PMID: 38499138). Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $74.99 Best $/mg — Vendors 1 Listings 1 capsule [Sign in for alerts ](/auth) Form Allcapsule Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Ostarine (MK-2866) capsules (60) capsule 60 capsules ● In Stock $74.99 BEST — — [Buy](https://disguisedalpha.com/product/ostarine-mk-2866/?coupon=reddit) Get Ostarine (Enobosarm, MK-2866) Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $74.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Ostarine (Enobosarm, MK-2866). [Sign in](/auth) Current low $74.99 as of Sep 7, 2026 7-day low $74.99 30-day low $74.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Ostarine (Enobosarm, MK-2866) [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $74.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### ITPP Performance Preclinical ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues. Research compound — IV infusion in studies, no established oral doses 36 studies View Profile ](/compound/itpp)[ ### LGD-4033 (Ligandrol) Performance Phase 2 LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095). t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616) Preclinical View Profile ](/compound/lgd-4033)[ ### PEG-MGF Performance Preclinical PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 Preclinical View Profile ](/compound/peg-mgf)[ ### RAD-140 (Testolone) Performance Phase 1 RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). t½ Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686) Preclinical View Profile ](/compound/rad-140)[ ### SLU-PP-332 Performance Preclinical SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism. Research compound — no established human doses. Animal studies: 10-50 mg/kg 8 studies View Profile ](/compound/slu-pp-332)[ ### YK-11 Performance Preclinical YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. t½ Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415) Preclinical View Profile ](/compound/yk-11) [ View Full Dosage Guide → Protocols, calculator & safety for Ostarine (Enobosarm, MK-2866) ](/guides/dosage/ostarine) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $74.99 [Buy Now](https://disguisedalpha.com/product/ostarine-mk-2866/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Not established from a retrieved human report; in rats the mean elimination half-life of radiolabeled GTx-024 was 0.6 h in males and 16.4 h in females (PMID: 24074268). Human plasma pharmacokinetics were characterized in phase 1 drug-interaction studies (PMID: 27105861) Molecular Weight 389.33 g/mol Administration Oral CAS Number 841205-47-8 Trial Phase Phase 3 0 [Full Dosage Guide](/guides/dosage/ostarine)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Ostarine (Enobosarm, MK-2866) used for in research? Ostarine is the market name for enobosarm, a nonsteroidal selective androgen receptor modulator first developed by GTx Inc under the codes GTx-024, MK-2866 and S-22. It was designed to switch on the androgen receptor in muscle and bone while acting only weakly on prostate and other reproductive tissue, and it was taken into clinical development for muscle wasting in cancer, for age-related loss of muscle, for androgen receptor positive breast cancer and for stress urinary incontinence. It has never been approved by the FDA or the EMA for any indication. Development rights now sit with Veru Inc, which is testing it as an add-on to GLP-1 receptor agonists to limit the loss of lean mass that accompanies rapid weight reduction. The androgen receptor is a nuclear receptor. Testosterone and dihydrotestosterone bind it, move it into the cell nucleus and change which genes are read. Enobosarm binds the same receptor but recruits a different set of co-regulator proteins, which is why its effects on muscle and bone are stronger than its effects on prostate and skin. Work in mice showed that the muscle response does not come only from satellite cells, since enobosarm still restored muscle weight in animals lacking the androgen receptor in that cell lineage (PMID: 26393303). In animals, enobosarm improved bone healing in ovariectomized rats (PMID: 31531719), improved muscle tissue in ovariectomized rats (PMID: 33042018) and improved bone in orchiectomized rats used as an osteoporosis model (PMID: 37378829). Not every animal result is favorable: in rats it blunted the effect of endurance training on submaximal endurance (PMID: 38451281) and did not add to the metabolic effect of exercise in obese rats (PMID: 37865959). In humans, a 12-week phase 2 trial in 120 healthy older men and postmenopausal women reported gains in total lean body mass and physical function against placebo (PMID: 22031847), and a phase 2 trial in patients with cancer-related weight loss reported gains in lean body mass (PMID: 23499390). The safety record is the part most often left out of marketing. Cholestatic and hepatocellular liver injury after ostarine use has been published as individual case reports, including a young man who needed albumin dialysis and took six months to return to normal bilirubin (PMID: 37871633), a hepatocellular case that resolved after stopping the supplement (PMID: 35655632) and cases involving ostarine with post-cycle drugs (PMID: 34141767). A systematic review of safety in healthy adults collected fifteen published cases of drug-induced liver injury across the SARM class along with a tendon rupture and a rhabdomyolysis case (PMID: 37218811). The FDA states that these products are unapproved drugs, are not dietary supplements, and lists liver injury and acute liver failure, heart attack, stroke, psychosis, infertility and testicular shrinkage among reported risks (FDA, Certain Bodybuilding Products Put Consumers at Risk, page updated December 2025). What is sold online is often not what the label says. In an analysis of 44 products marketed as SARMs, only 52 percent contained a SARM at all, 39 percent contained a different unapproved drug, and the labeled amount matched the measured amount in only 41 percent (PMID: 29183075). What forms does Ostarine (Enobosarm, MK-2866) come in? Ostarine (Enobosarm, MK-2866) is available in capsule form. How much does Ostarine (Enobosarm, MK-2866) cost? Prices start at $74.99 across 1 verified vendor. How do I compare Ostarine (Enobosarm, MK-2866) vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### ITPP Performance Preclinical ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues. Research compound — IV infusion in studies, no established oral doses 36 studies View Profile ](/compound/itpp)[ ### LGD-4033 (Ligandrol) Performance Phase 2 LGD-4033, usually sold as ligandrol, is a nonsteroidal selective androgen receptor modulator that Viking Therapeutics took into clinical development under the code VK5211 (NCT02578095). t½ Long elimination half-life in humans with dose-proportional accumulation over 21 days of daily dosing in healthy young men; the report describes the profile without giving a single value in its summary (PMID: 22459616) Preclinical View Profile ](/compound/lgd-4033)[ ### PEG-MGF Performance Preclinical PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of Mechano Growth Factor (MGF) — an alternatively spliced variant of IGF-1 produced locally in muscle and other tissues in response to mechanical loading or damage. t½ Native MGF: very short (minutes) due to rapid proteolysis. PEG-MGF: PEGylation is intended to extend this substantially (community estimates up to roughly 1 day), but there are no published human pharmacokinetic data to confirm a specific value. 200 Preclinical View Profile ](/compound/peg-mgf)[ ### RAD-140 (Testolone) Performance Phase 1 RAD-140, sold as testolone and given the international nonproprietary name vosilasarm, is a nonsteroidal selective androgen receptor modulator developed at Radius Health, whose scientists reported the first-in-human trial (PMID: 34565686), and first described in the medicinal chemistry literature as a compound with an oxadiazole core designed for oral androgen receptor activity with tissue selectivity (PMID: 24900290). t½ Terminal half-life 44.7 hours in humans, measured in a first-in-human phase 1 study in postmenopausal women with metastatic breast cancer (PMID: 34565686) Preclinical View Profile ](/compound/rad-140)[ ### SLU-PP-332 Performance Preclinical SLU-PP-332 is the first-generation synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) developed by the laboratory of Thomas Burris at Saint Louis University and reported in a landmark 2023 publication that established ERR pan-agonism as a pharmacologically tractable exercise-mimetic drug mechanism. Research compound — no established human doses. Animal studies: 10-50 mg/kg 8 studies View Profile ](/compound/slu-pp-332)[ ### YK-11 Performance Preclinical YK-11 is a synthetic steroid, not a nonsteroidal SARM, despite being sold alongside them. t½ Not established. In a human elimination study using deuterium-labeled YK-11, no intact parent compound was seen in urine; unconjugated metabolites disappeared within 24 hours and glucuronidated and sulfated metabolites remained traceable beyond 48 hours (PMID: 30379415) Preclinical View Profile ](/compound/yk-11) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-ostarine) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋